Market Research Report
Global Gonorrhea Therapeutics Market with COVID-19 Impact Analysis, By Type, By Sampling Rate, By Application and By Region - Size, Share, & Forecast from 2021-2027
|Published by||AnalystView Market Insights||Product code||997998|
|Published||Content info||290 Pages
Delivery time: 2-3 business days
|Global Gonorrhea Therapeutics Market with COVID-19 Impact Analysis, By Type, By Sampling Rate, By Application and By Region - Size, Share, & Forecast from 2021-2027|
|Published: March 1, 2021||Content info: 290 Pages||
The global Gonorrhea Therapeutics market size was valued at USD 980.2 million by 2019, growing with 4.1% CAGR during the forecast period, 2021-2027.
Gonorrhea Therapeutics is an infection caused by a sexually transmitted bacterium that infects both males and females. The primary factors such as the rising prevalence of gonorrhea, implementation of national screening programs, and growing public awareness are propelling the growth of the gonorrhea therapeutics market. According to the Centers for Disease Control and Prevention (CDC), around 700,000 new cases of gonorrhea are detected each year. In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) has granted USD 41.6 million over five years to support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea, and chlamydia. Thus, the growing prevalence of STDs increases patient awareness through national campaigns, and growing government initiatives are anticipated to drive market growth. However, stringent regulatory scenarios and social stigma associated with patients visiting STD clinics are expected to restrain the growth of the United States market in the forecast period.
The gonorrhea therapeutics market is divided based on the treatment, gonococcal infection, application, distribution channel, route of administration, and region.
By treatment, the market has been segmented into monotherapy and dual therapy. Gonorrhea, caused by Neisseria gonorrhoeae, is the second most common bacterial STI and results in substantial morbidity. The dual therapy segment is estimated to dominate the United States market, and this trend is expected to continue over the forecast period. Dual therapy with ceftriaxone and azithromycin is recommended as the first-line regimen for the treatment of gonorrhea.
On the basis of gonococcal infection, the market is categorized as uncomplicated gonococcal infection, gonococcal arthritis & gonococcal meningitis, and endocarditis. Amidst this category, the uncomplicated gonococcal infection has a major share in the gonorrhea therapeutics market. Uncomplicated infections are much more common, encompassing any urogenital, anogenital, or pharyngeal infection caused by N gonorrhea that does not result in bacteremia.
By application, the market has been segmented into clinics and hospitals. Amidst this category, hospitals have a major share in the gonorrhea therapeutics market as hospitals remain preferred care centers for patients diagnosed with gonorrhea.
Based on the distribution channel, the United States gonorrhea therapeutics market has been divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacy segment is estimated to dominate the gonorrhea therapeutics market by the end of 2031. The sales of gonorrhea therapeutics are projected to witness significant uptake from hospital pharmacies, as hospitals remain preferred care centers for patients diagnosed with gonorrhea.
Key players operating in the global gonorrhea therapeutics market include Merck & Co., Inc., GlaxoSmithKline plc., Pfizer Inc, AstraZeneca, Danaher., Hologic, Inc., Abbott, Becton Dickinson and Company, F. Hoffmann-La Roche Ltd. These players are adopting strategies such as new product development, partnerships, and acquisitions to remain competitive in the United States gonorrhea therapeutics market.
Also, several leading organizations and companies have started to develop new medicines and treatments for the treatment of the global gonorrhea therapeutics market. For instance, in Sept 2019, the Global Antibiotic Research and Development Partnership (GARDP), a not-for-profit organization has planned to develop drug-resistant infections treatments for gonorrhea by partnering with Entasis Therapeutics a clinical-stage biopharmaceutical company. The company focused on the discovery and development of novel antibacterial products and recently started a global phase 3 pivotal trial with Zoliflodacin drug for gonorrhea. Zoliflodacin is a novel, first-in-class oral antibiotic treatment drug for uncomplicated gonorrhea.
Key features of the study:
This proposed research study on Gonorrhea Therapeutics market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2020-2027), considering 2019 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Gonorrhea Therapeutics market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Gonorrhea Therapeutics market
Impact of COVID-19 on Gonorrhea Therapeutics market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Gonorrhea Therapeutics market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the Gonorrhea Therapeutics market, we have also included competitive landscape and key innovator analysis for the Gonorrhea Therapeutics market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and TYPE attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Gonorrhea Therapeutics market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new TYPE launch, research & development, regional expansion of major participants involved in the electric tooth brush market on global as well as regional level.
The global Gonorrhea Therapeutics market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL GONORRHEA THERAPEUTICS MARKET KEY PLAYERS
Becton Dickinson and Company
Merck & Co., Inc.
Sun Pharmaceutical Industries Ltd,
Hikma Pharmaceuticals PLC,
Mayne Pharma Group Limited
Nostrum Laboratories Inc,
Genocea Biosciences, Inc.
GLOBAL GONORRHEA THERAPEUTICS MARKET, BY GONOCOCCAL INFECTION
Uncomplicated Gonococcal Infection
Gonococcal Meningitis and Endocarditis
GLOBAL GONORRHEA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
GLOBAL GONORRHEA THERAPEUTICS MARKET, BY TREATMENT
GLOBAL GONORRHEA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
GLOBAL GONORRHEA THERAPEUTICS MARKET, BY APPLICATION
GLOBAL GONORRHEA THERAPEUTICS MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
The Middle East and Africa
United Arab Emirates
Rest of MEA
List of Tables
List of Figures